Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 16/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.68 |
| ▸ | OPRD1 | P41143 | 9/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10060840 | 1.00 | OPRL1 (0.68) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL13605139 | 0.92 | OPRL1 (0.61) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL11762583 | 0.90 | OPRL1 (0.59) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL1724862 | 0.89 | OPRL1 (0.57) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL1109741 | 0.89 | OPRL1 (0.57) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL60129 | 0.87 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL29195226 | 0.87 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1POLB | |
| Ammonia Solution, Strong SCHEMBL29195223 | 0.87 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL1040024 | 0.87 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1POLB | |
| SCHEMBL16469256 | 0.87 | OPRL1 (0.55) | OPRL1OPRM1OPRK1OPRD1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121717728-B | Benzamide/benzenesulfonamide compound containing aryl butanone structure, and preparation method and application thereof | YANTAI UNIVERSITY (CN) | 2026-05-26 | — | — | CN | claimed |
| US-20250129116-A1 | CYCLOPROPANOL AS A BIOORTHOGONAL WARHEAD FOR ELECTROCHEMICALLY CONTROLLED BIOCONJUGATION APPLICATIONS | UNIVERSITY OF SOUTH CAROLINA | 2025-04-24 | — | — | US | claimed |
| CN-110294972-A | A kind of ink | 深圳TCL工业研究院有限公司 | 2019-10-01 | — | — | CN | claimed |
| CN-121717728-B | Benzamide/benzenesulfonamide compound containing aryl butanone structure, and preparation method and application thereof | YANTAI UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260118361-A1 | FLUOROGENIC BIOCONJUGATION OF CYCLOPROPANOL-BASED FLUOROPHORES FOR BIOLOGICAL APPLICATIONS | UNIV SOUTH CAROLINA (US) | 2026-04-30 | — | — | US | disclosed |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20250129116-A1 | CYCLOPROPANOL AS A BIOORTHOGONAL WARHEAD FOR ELECTROCHEMICALLY CONTROLLED BIOCONJUGATION APPLICATIONS | UNIVERSITY OF SOUTH CAROLINA | 2025-04-24 | — | — | US | disclosed |
| CN-116253677-B | Method for synthesizing pyridine compound by utilizing micro-channel reaction device | 南京工业大学 | 2025-01-28 | — | — | CN | disclosed |
| CN-118993956-A | Preparation method of sulfonyl bridged 1, 7-dicarbonyl compound | 安阳师范学院 | 2024-11-22 | — | — | CN | disclosed |
| CN-118978472-A | Preparation method of indolone compound connected with gamma-ketosulfone structure | 安阳师范学院 | 2024-11-19 | — | — | CN | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-8975235-B2 | Lysophosphatidic acid receptor antagonists | INTERMUNE, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| WO-2013025733-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. (US) | 2013-02-21 | — | — | WO | disclosed |
| EP-1144415-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042045-A2 | FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS | WARNER-LAMBERT COMPANY (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-0192638-A1 | LEMON-YELLOW DIAZO COMPOSITIONS | JAMES RIVER-GRAPHICS, INC. (US) | 1986-09-03 | — | — | EP | disclosed |
| WO-1986001505-A1 | LEMON-YELLOW DIAZO COMPOSITIONS | JAMES RIVER GRAPHICS, INC. (US) | 1986-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129116-A1 | CYCLOPROPANOL AS A BIOORTHOGONAL WARHEAD FOR ELECTROCHEMICALLY CONTROLLED BIOCONJUGATION APPLICATIONS | CBR3, CBR1, BBOX1 | OPRL1 2897/4885OPRM1 2318/4885OPRK1 1571/4885 |
| US-20130072449-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | OPRL1 311/4885OPRM1 1387/4885OPRK1 700/4885 |
| US-20260118361-A1 | FLUOROGENIC BIOCONJUGATION OF CYCLOPROPANOL-BASED FLUOROPHORES FOR BIOLOGICAL APPLICATIONS | QSOX1, CBR1, CBR3 | OPRL1 589/4885OPRM1 905/4885OPRK1 893/4885 |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC3, HDAC1 | OPRL1 2077/4885OPRM1 1612/4885OPRK1 2584/4885 |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | OPRL1 4562/4885OPRM1 3279/4885OPRK1 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.